FOLFIRINOX Improves PFS Compared with Gemcitabine in Patients with Locally Advanced Pancreatic Carcinoma By Ogkologos - May 26, 2025 580 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PRODIGE 29-UCGI 26 (NEOPAN) study Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR Bringing the Cancer Community Back Together at ASCO Annual Meeting: Why... June 2, 2022 FDA Approves Mitomycin Intravesical Solution for Recurrent Low Grade Intermediate Risk... July 31, 2025 First New Drug in Years Reduces Recurrence in High-risk Hormone Receptor... September 20, 2020 Neoadjuvant Followed by Adjuvant Pembrolizumab Prolongs Event-Free Survival Compared to Adjuvant... March 8, 2023 Load more HOT NEWS Comme louer son affaire en compagnie de tacht mahometane? (2023) Zanubrutinib’s Approval Improves Targeted Treatment for CLL Predictive Performance of DNA Methylation-based Test in Combination with HPV16/18 Genotyping... Screening for Many Cancers with One Test: Uncertainty Abounds
